Abstract:Background: Despite mechanistic studies linking retinol and RBP4 (retinol binding protein 4) to the pathogenesis of cardiovascular diseases (CVD) and type 2 diabetes (T2D), epidemiological evidence is still conflicting. We investigated whether conflicting results of previous studies may be explained by differences in the association of retinol and RBP4 with cardiometabolic risk across subgroups with distinct sex, hypertension state, liver, or kidney function. Methods: We used case-cohorts nested in the EPIC (European Prospective Investigation Into Cancer and Nutrition)-Potsdam cohort (N=27 548) comprising a random sample of participants (n=2500) and all physician-verified cases of incident CVD (n=508, median follow-up time 8.2 years) and T2D (n=820, median follow-up time 6.3 years). We estimated nonlinear and linear multivariable-adjusted associations between the biomarkers and cardiometabolic diseases by restricted cubic splines and Cox regression, respectively, testing potential interactions with hypertension, liver, and kidney function. Additionally, we performed 2-sample Mendelian Randomization analyses in publicly available data. Results: The association of retinol with cardiometabolic risk was modified by hypertension state (P interaction CVD<0.001; P interaction T2D<0.001). Retinol was associated with lower cardiometabolic risk in participants with treated hypertension (hazard ratioper SD [95% CI]: CVD, 0.71 [0.56-0.90]; T2D, 0.81 [0.70-0.94]) but with higher cardiometabolic risk in normotensive participants (CVD, 1.32 [1.06-1.64]; T2D, 1.15 [0.98-1.36]). Our analyses also indicated a significant interaction between RBP4 and hypertension on CVD risk (P interaction=0.04). Regarding T2D risk, we observed a u-shaped association with RBP4 in women (P nonlinearity=0.01, P effect=0.02) and no statistically significant association in men. The biomarkers' interactions with liver or kidney function were not statistically significant. Hypertension state-specific associations for retinol concentrations with cardiovascular mortality risk were replicated in National Health and Nutrition Examination Survey III. Conclusions: Our findings suggest a hypertension-dependent relationship between plasma retinol and cardiometabolic risk and complex interactions of RBP4 with sex and hypertension on cardiometabolic risk.

The metabolic role of retinol binding protein 4: an update

Retinol-binding Protein-4 and Nonalcoholic Fatty Liver Disease

Retinol binding protein 4 in relation to diet, inflammation, immunity, and cardiovascular diseases

[The perspectives of application of retinol-binding protein as a biomarker of risk of cardiovascular pathology]

Increased Retinol-Free RBP4 Contributes to Insulin Resistance in Gestational Diabetes Mellitus

Recent Progress in Relationship Between RBP4 and Metabolic Syndrome

Assessment of Retinol Binding Protein 4 in Nutritional Diseases and Liver or Kidney Diseases

Retinol binding protein 4 and type 2 diabetes: from insulin resistance to pancreatic β-cell function

Retinol Binding Protein 4 Stimulates Hepatic SREBP-1 and Increases Lipogenesis through PGC-1 beta-dependent Pathway Short title : RBP 4 promotes hepatic lipogenesis

The Role Of Circulating Rbp4 In The Type 2 Diabetes Patients With Kidney Diseases: A Systematic Review And Meta-Analysis

Retinol and Retinol Binding Protein 4 Levels and Cardiometabolic Disease Risk

Adipokine Retinol Binding Protein 4 and Cardiovascular Diseases

Serum Retinol Binding Protein 4 and Cardiovascular Disease

Retinol Binding Protein 4 Stimulates Hepatic Sterol Regulatory Element-Binding Protein 1 and Increases Lipogenesis Through the Peroxisome Proliferator-Activated Receptor-Γ Coactivator 1Β-Dependent Pathway.

Retinol Binding Protein 4 Induces Mitochondrial Dysfunction and Vascular Oxidative Damage.

Retinol-Binding Protein 4 Induces Hepatic Mitochondrial Dysfunction and Promotes Hepatic Steatosis

Relationship between type 2 diabetes and retinol binding protein 4 and its genetic polymorphism

Serum Retinol Binding Protein 4 and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

Elevated Retinal Retinol-Binding Protein 4 Levels in Diabetic Mice Can Induce Retinal Neurodegeneration Through Microglia

Expression and Regulation of Retinol Binding Protein 4 Mrna in Human Adipose Tissue in Obese and Type 2 Diabetics

Associations of RBP4 with lipid metabolism and renal function in diabetes mellitus